Merck looks to Facebook for employee portal, CSR effort

Share this article:
Merck looks to Facebook for employee portal, CSR effort
Merck looks to Facebook for employee portal, CSR effort
Merck is launching a major corporate social responsibility initiative, reports PRWeek (subscription required), which profiled communications chief Adele Ambrose in its March issue.

The campaign, coming a year after Merck's acquisition of Schering-Plough, will focus on the company's role in global health. Merck is also retooling its employee portal “to include online community building capabilities similar to Facebook profiles,” said PRWeek. Still stinging from the Vioxx debacle, the company will also move forward with some consumer-facing social media initiatives, in part as a means of addressing critics.

“One change in the way we're managing communications and our reputation is this notion of not expecting people to know your story if you're not telling your own story,” Ambrose told PRWeek. “You really need to look at every possible touchpoint the company has and tell a consistent story about who you are and what you stand for.”

Ambrose, who joined Merck from AT&T in 2007, is looking to raise the profile of the corporate brand in association with health and wellness while making key execs like chief medical officer Michael Rosenblatt and CEO Ken Frazier available to news outlets.

“She doesn't pull punches,” Frazier told PRWeek. “She has had a profound impact on the company, in how well it represents its point of view to the outside world and how well we understand the outside world's expectations of Merck.”     
Share this article:

Email Newsletters

More in News

Five things for pharma marketers to know: Thursday, August 21

Five things for pharma marketers to know: Thursday, ...

An Ebola survivor is set to leave Emory University Hospital, but the cause of the cure is uncertain, the FDA has approved a new type 1 diabetes test, and the ...

Sanofi expands Gaucher disease portfolio

Sanofi expands Gaucher disease portfolio

The oral medication Cerdelga joins Cerezyme in its Gaucher disease arsenal. Sanofi expects the drug will be priced "on par" with Cerezyme, which goes for around $300,000 a year in ...

Amicus seeks to upset Fabry market

Amicus seeks to upset Fabry market

Phase-III tests indicate patients may be able to switch from injectable enzyme-replacement therapies, like Fabrazyme, to the firm's oral drug.